Mild Water-Filtered Near Infrared Whole-Body-Hyperthermia as an Adjunct in the Treatment of Fibromyalgia
The purpose of the study is to evaluate whether mild walter-filtered near infrared hyperthermia produces an additional benefit when applied as an adjunct to standard multimodal rehabilitation compared to standard multimodal rehabilitation only in patients with fibromyalgia.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Randomized Controlled Trial on the Effectiveness of Mild Water-Filtered Near Infrared Hyperthermia as an Adjunct to a Standard Multimodal Rehabilitation in the Treatment of Fibromyalgia|
- affective pain (German version of the McGill Pain Questionnaire)
- sensory pain (German version of the McGill Pain Questionnaire)
- pain intensity (visual analogue scale)
- Fibromyalgia related quality of life(German version of the Fibromyalgia Impact Questionnaire)
- tender point assessment(mean tender point pain threshold, total tender point intensity, tender point count)
- adverse events, side effects
|Study Start Date:||January 2004|
|Estimated Study Completion Date:||July 2005|
Mild systemic heat agents, including infrared whole-body hyperthermia, are used as treatment options in multimodal rehabilitation programs for fibromyalgia in Germany. However, no randomized controlled clinical trial exists on their effectiveness for this condition.
This study is designed as an add-on study to evaluate the additional benefit of mild walter-filtered near infrared hyperthermia and a standard multimodal rehabilitation program compared to a standard multimodal rehabilitation program only. Standard multimodal rehabilitation is configured as usually applied in clinical trials with exercise, cognitive behavioral therapy, and health education as the main treatment components.
Mild walter-filtered near infrared hyperthermia (heating-up to 38.1 degrees C body core temperature followed by a 15-min heat retention period) is administered twice a week over 3 weeks during a rehabilitation hospital stay.
Primary outcome measures are measured at baseline, postintervention, 3 and 6 months postintervention. Analysis is done by intention to treat, for significance testing Repeated Measures ANCOVA is used.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00324441
|Rehabilitationsklinik Hoher Meissner|
|Bad Sooden-Allendorf, Hessen, Germany, 37242|
|Study Chair:||Thomas Brockow, MD||FBK Bad Elster|